R-CHOP is a combination of five drugs used to treat certain types of non-Hodgkin lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). Each letter in the name stands for a different medication: rituximab, cyclophosphamide, hydroxydaunomycin (doxorubicin), Oncovin (vincristine), and prednisone. It has been the standard first-line treatment for DLBCL for over two decades, and roughly 60% of patients treated with R-CHOP remain disease-free at five years.
What Each Drug Does
The five drugs in R-CHOP work through different mechanisms, which is part of why the combination is effective. Attacking cancer cells from multiple angles makes it harder for them to survive.
Rituximab (R) is not a traditional chemotherapy drug. It’s a targeted therapy called a monoclonal antibody. It locks onto a protein called CD20 that sits on the surface of lymphoma cells, essentially tagging them so your immune system can find and destroy them. Because it targets a specific protein rather than all fast-dividing cells, it works differently from the other four drugs in the regimen.
Cyclophosphamide (C), doxorubicin (H), and vincristine (O) are the chemotherapy backbone. All three destroy rapidly dividing cells, but they do so through different chemical pathways. Doxorubicin is sometimes called the “red devil” because of its bright red color. Vincristine’s brand name, Oncovin, gives the regimen its “O.”
Prednisone (P) is a steroid. It directly kills lymphoma cells and stops them from growing, but it also serves a practical purpose during treatment: it helps reduce nausea and lowers the risk of allergic reactions to rituximab.
How Treatment Is Given
R-CHOP is typically given in cycles, with each cycle lasting 21 days. Most people receive six cycles, meaning the full course of treatment runs about four and a half months. On the first day of each cycle, you go to an infusion center where four of the five drugs (rituximab, cyclophosphamide, doxorubicin, and vincristine) are delivered through an IV. The process can take several hours, especially during the first cycle when rituximab is given more slowly to watch for reactions. Prednisone is taken as a pill at home, usually for five days at the start of each cycle.
The remaining two weeks of each cycle are recovery time. Your body uses that window to bounce back before the next round. Blood tests are typically done before each cycle to make sure your blood counts have recovered enough to proceed safely.
What R-CHOP Treats
R-CHOP is primarily used for B-cell non-Hodgkin lymphomas, the most common being DLBCL. It’s considered the gold standard first-line treatment for this disease. It may also be used for other types of B-cell lymphoma, including follicular lymphoma when aggressive treatment is needed. The rituximab component only works on cancers that express the CD20 protein, which is why this regimen is specific to B-cell lymphomas rather than cancers in general.
How Effective R-CHOP Is
In a large international trial (the POLARIX study, with 879 patients), the five-year progression-free survival rate for R-CHOP was about 59%. That means roughly six out of ten patients had no return of their lymphoma five years after treatment. For patients with lower-risk disease, outcomes are considerably better. Overall survival rates, which account for people who relapse but respond to further treatment, tend to be higher than progression-free numbers.
A newer regimen called Pola-R-CHP, which swaps vincristine for a different drug, showed a modest improvement in the same trial, with a five-year progression-free survival of about 65%. Both regimens remain in use, and the choice between them depends on individual factors your oncologist will weigh.
Common Side Effects
Most side effects from R-CHOP stem from the chemotherapy drugs hitting healthy fast-dividing cells alongside cancer cells. Hair follicles, the gut lining, and bone marrow are the most affected.
Hair loss is one of the most visible effects. Most people start losing hair within three weeks of the first infusion. It grows back after treatment ends, though the texture or color may be slightly different at first.
Other common side effects include:
- Nausea and vomiting
- Fatigue, sometimes severe
- Feeling chilled or feverish
- Bruising or bleeding more easily (from lowered platelet counts)
- Tingling or numbness in the hands and feet
- Mouth sores
- Constipation or diarrhea
- Trouble sleeping and mood changes (often from prednisone)
One thing that catches people off guard: your urine will turn reddish or pink for about 48 hours after each infusion. This is simply the doxorubicin passing through your system. It’s not blood, and it’s completely expected.
Many people have a mild infusion reaction during the first cycle, particularly to rituximab. This can include chills, fever, or a rash. The infusion team monitors for this and can slow the drip or give medications to manage it. Reactions tend to be milder or absent in later cycles.
Serious Risks to Know About
Two components of R-CHOP carry risks that extend beyond typical chemo side effects, and your medical team will monitor for both throughout treatment.
Heart damage from doxorubicin. Doxorubicin belongs to a class of drugs called anthracyclines, which can weaken the heart muscle over time. This risk increases with higher cumulative doses, though it can occur at lower doses too. People who are very young, elderly, female, or who have a history of heart disease face higher risk. Your heart function will be checked before treatment starts, typically with an echocardiogram or similar imaging, and may be rechecked during or after treatment if there are concerns.
Nerve damage from vincristine. The tingling and numbness in hands and feet that many patients experience is a form of nerve damage called peripheral neuropathy. For most people it’s mild and improves after treatment ends, but in some cases it can be more significant or persistent. Vincristine can also affect the autonomic nerves that control things like digestion and heart rate, though this is less common. If numbness becomes severe during treatment, your oncologist may adjust the vincristine dose.
Because R-CHOP suppresses the immune system significantly, infections are a real concern, particularly in the week or two after each infusion when white blood cell counts are at their lowest. Some patients receive injections of a growth factor to help white blood cell counts recover faster. Fever during treatment should always be taken seriously, as it can signal an infection that needs prompt attention.
What Recovery Looks Like
Each cycle follows a predictable pattern. The first few days after infusion tend to be the roughest, with nausea, fatigue, and general malaise peaking around days two through five. The steroid (prednisone) can actually make you feel energized or restless during the days you’re taking it, followed by a crash when you stop. By the second week of each cycle, most people start feeling more like themselves, and the third week is typically the best before the next round begins.
After the final cycle, recovery is gradual. Fatigue often lingers for weeks to months. Hair typically starts regrowing within a few weeks of finishing treatment. Numbness in the hands and feet may take longer to resolve, sometimes six months or more. Heart function monitoring may continue periodically for patients who received higher cumulative doses of doxorubicin, since cardiac effects can appear months or even years later.